Treating and evaluating inflammatory disorders
OwnerLinda C. Burkly, Timothy Zhenginventors
Life of this patent
Estimating the term…
Abstract
Methods of treating inflammatory disorders, such as rheumatoid arthritis, by modulating TWEAK and TNF-α are disclosed, as are other methods.
Claims54
A method comprising:
- administering, to a human subject who has rheumatoid arthritis, a TWEAK blocking agent in combination with a TNF-α blocking agent, in amounts and for a time to provide a therapeutic effect.
A method comprising:
- administering, to a human subject who has rheumatoid arthritis, a TWEAK blocking agent in combination with another biologic DMARD, in amounts and for a time to provide a therapeutic effect.
A kit that comprises a TWEAK blocking agent and a TNF-α blocking agent, wherein the agents are provided as separate pharmaceutical compositions or a single pharmaceutical composition.
A pharmaceutical composition that includes:
- a TWEAK blocking agent;
- and
- a TNF-α blocking agent.
A method comprising:
- identifying a subject who has TWEAK and TNF-α mediated inflammation;
- and
- administering to the subject:
- (i) a TWEAK blocking agent;
- (ii) a TNF-α blocking agent;
- or (iii) a combination of (i) and (ii).
A method comprising:
- administering, to a human subject who has rheumatoid arthritis, and who is being or has been withdrawn from a TNF-α blocking agent, a TWEAK blocking agent in an amount and for a time effective to provide a therapeutic effect.
A method comprising:
- detecting an adverse event in a human subject who has rheumatoid arthritis, wherein the subject is being treated with a TNF-α blocking agent, but not a TWEAK blocking agent;
- and
- administering, to the subject, a TWEAK blocking agent in an amount and for a time effective to provide an overall therapeutic effect.
A method comprising:
- administering, to a human subject who has rheumatoid arthritis, and who is being or has been withdrawn from a DMARD other than a TWEAK blocking agent, a TWEAK blocking agent in an amount and for a time to provide a therapeutic effect.
A method comprising:
- administering, to a human subject who has an inflammatory disorder, a TWEAK blocking agent in combination with a TNF-α blocking agent, in amounts and for a time to provide a therapeutic effect, wherein the inflammatory disorder is one that a TNF-α blocking agent does not exacerbate.
A method of reducing joint inflammation, the method comprising identifying a subject having joint inflammation, and administering to the subject a TWEAK blocking agent in combination with a TNF-α blocking agent.
Dependencies are inferred from the claim text.